Pharmapace will become a wholly-owned subsidiary of WuXi Clinical and will continue to focus on growing its core biometrics competences.
Zuellig Pharma has acquired Singapore-based healthtech startup Klinify for an undisclosed amount.
Under the terms of the collaboration with BeiGene, Ambrx will receive US$10 million to fund the initial discovery and research activities for novel biologic drug candidates.
ASLAN Pharmaceuticals will focus on clinical development of varlitinib while BioGenetics will obtain the necessary regulatory approvals for the use of the drug in South Korea.
The collaboration leverages BioLingus' platform for stabilizing and delivering drugs via tissues under the tongue.
The acquisition of Shire allows Takeda to expand its R&D efforts in four therapeutic areas: oncology, gastroenterology, neuroscience and rare diseases.
The treatment method, which relies on electric fields to destroy tumors, can now be used to treat patients in Hong Kong diagnosed with an aggressive type of brain cancer.
Sintilimab, a fully human anti-PD-1 therapeutic monoclonal antibody, was co-discovered by Innovent and Adimab and jointly developed by Innovent and Eli Lilly in China.
The drug, ETC-206, was shown to be well tolerated in human trials and specifically targets cancer cells while leaving normal cells unharmed.